In order to overcome the intrinsic limitations of retrospective studies, and to move above commented markers towards the clinical practice, a prospective case-control study, named PRESSING (PRimary rESiStance IN RAS and BRAF wild-type metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies), was recently conducted. Here, EGFR is linked to metastatic colorectal cancer.